NPC Comments on CMS Medicare Drug Price Negotiation Program

NPC's comments highlight concerns about the agency's guidance regarding the implementation of Medicare Drug Price Negotiation and the potential for unintended consequences, including less biopharmaceutical innovation, fewer treatment options, and lower life expectancy.

Scientist working with a pipette and test tubes

NPC submitted comments to the Centers for Medicare & Medicaid Services in response to the solicitation for input regarding the Medicare Drug Price Negotiation Program: Initial Memorandum, Implementation of Sections 1191 – 1198 of the Social Security Act for Initial Price Applicability Year 2026. The comments outline concerns about CMS' guidance for the implementation of the new price-setting mechanism created by the Inflation Reduction Act, and how its implementation will reduce incentives for the development of innovative new medicines and impact patient access. 

Read the comment letter